Form 8-K - Current report:
SEC Accession No. 0001437749-20-002715
Filing Date
2020-02-14
Accepted
2020-02-14 12:02:58
Documents
3
Period of Report
2020-02-14
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K navb20200214_8k.htm 8-K 52769
2 EXHIBIT 99.1 ex_172787.htm EX-99.1 14337
3 EXHIBIT 99.2 ex_172788.htm EX-99.2 10092
  Complete submission text file 0001437749-20-002715.txt   78471
Mailing Address 4995 BRADENTON AVENUE SUITE 240 DUBLIN OH 43017
Business Address 4995 BRADENTON AVENUE SUITE 240 DUBLIN OH 43017 6147937500
NAVIDEA BIOPHARMACEUTICALS, INC. (Filer) CIK: 0000810509 (see all company filings)

EIN.: 311080091 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-35076 | Film No.: 20616357
SIC: 2835 In Vitro & In Vivo Diagnostic Substances